https://doi.org/10.5812/archcid.22065

Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment

authors:

avatar Masoud Mardani 1 , *

Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Archives of Clinical Infectious Diseases: Vol.9, issue 3; e22065
published online: June 25, 2014
article type: Editorial
received: April 27, 2014
accepted: May 14, 2014

how to cite: Mardani M. Dalbavancin, Oritavancin and Tedizolid are Safe and Effective for Skin Infection Treatment. Arch Clin Infect Dis. 2014;9(3):e22065. https://doi.org/10.5812/archcid.22065.

Acute bacterial skin and skin structure infections are among the most common reasons for hospitalization of adults (1). These infections are most often caused by Staphylococcus aureus and streptococci (2). Methicillin-resistant S. aureus (MRSA) account for many of these infections and present a particular treatment challenge because current therapies are limited by toxicity, resistance, or the lack of an oral formulation (3). Patients with skin or skin structure infections have three new antibiotic options, which have similar efficacy and safety profiles as vancomycin.

Glycopeptides, such as vancomycin are the most available agents with in vitro and in vivo activity against gram-positive infection. Dalbavancin (Durata Therapeutics) is a lipoglycopeptide antibiotic agent with in vitro and in vivo activity against gram-positive pathogens and a minimal inhibitory concentration (MIC) of this agent is required to inhibit the growth of 90% of the isolates (MIC90) (4). Oritavancin, a synthetic analog of vancomycin that also has activity against gram-positive bacteria. In a double-blind, placebo-controlled study, oritavancin and IV vancomycin were compared for the treatment of patients with acute bacterial skin and skin structure infection (SOLO I); patients were randomly assigned to receive either a single-dose intravenous oritavancin or intravenous vancomycin twice daily and treatment was successful for 82.3% of the oritavancin group and 78.9% of the vancomycin group (5). Tedizolid is a novel oxazolidinone antibacterial drug designed to provide enhanced activity against gram-positive pathogens. The efficacy and safety of intravenous and oral tedizolid for treatment of patients with acute bacterial skin and skin-structure infections has been established by some studies. Intravenous to oral once-daily tedizolid 200 mg for 6 days is non-inferior to twice-daily linezolid 600 mg for 10 days for treatment of patients with acute bacterial skin and skin-structure infections. Tedizolid could become a useful option for the treatment of acute bacterial skin and skin-structure infections in the hospital and outpatient settings (6). Studies have shown that the efficacy of dalbavancin administered once weekly, Oritavancin single dose and tedizolid 200 mg daily for 6 days are not inferior to that of a conventional twice daily antibiotic regimen with vancomycin or other glycopeptides and the early primary end point of cessation of the spread of infection and the absence of fever showed a consistent treatment effect regarding a reduction in the area of infection (4-6). Patients treated with dalbavancin had fewer adverse events than those treated with vancomycin and linezolid. However, further evaluation and monitoring is necessary as more patients are exposed to these agents; according to preliminary data, the adverse-effect profile of oritavancin and dalbavancin of these lipoglycopeptides is generally similar to that of drugs currently used to treat severe gram-positive infections (7). In the recent years, despite of suitable treatments in terms of cost befit and availability for gram-positive infections in Iran, it seems that the old treatment of gram-positive infection such as vancomycin is still prescribed by Iranian physicians. Studies comparing new and old treatments can lead Iranian physicians to optimal choice for treatment of gram-positive infections.

References

  • 1.

    Jenkins TC, Knepper BC, Sabel AL, Sarcone EE, Long JA, Haukoos JS, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011;171(12):1072-9. [PubMed ID: 21357799]. https://doi.org/10.1001/archinternmed.2011.29.

  • 2.

    Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin infect dis. 2011:ciq146.

  • 3.

    Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007;357(4):380-90. [PubMed ID: 17652653]. https://doi.org/10.1056/NEJMcp070747.

  • 4.

    Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407-15. [PubMed ID: 16231250]. https://doi.org/10.1086/497271.

  • 5.

    Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-79. [PubMed ID: 24897082]. https://doi.org/10.1056/NEJMoa1310480.

  • 6.

    Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014. [PubMed ID: 24909499]. https://doi.org/10.1016/S1473-3099(14)70737-6.

  • 7.

    Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30(1):80-94. [PubMed ID: 20030476]. https://doi.org/10.1592/phco.30.1.80.